Abstract |
Systematic data on the ability of pegfilgrastim to mobilize stem cells after chemotherapy are scarce. We evaluated the efficacy of a single 6 mg dose of pegfilgrastim for mobilizing peripheral blood stem cells (PBSC) in aggressive lymphoma patients. Between July 2004 and October 2005, 17 aggressive non-Hodgkin's lymphoma and 11 poor-risk Hodgkin's lymphoma were treated with cycles containing cisplatin-aracytin. At the end of chemotherapy, the patients received 6 mg of pegfilgrastim. Duration of grade 4 neutropenia, adverse events, time to neutrophil recovery, peak and harvest of CD34+ cells were recorded. Twenty-seven out of 28 patients harvested a median of 17.3 x 10(6)/CD34+ cells (range 2.5-28.9) after a median of 9 days (range 8-12 days), with a single apheresis procedure in 25 cases. All patients had grade 3-4 neutropenia, median duration 3 days. The only adverse event was mild bone pain. To date, 13 patients have been autografted with a median of 15.4 x 10(6) CD34+ pegfilgrastim-mobilized cells per kg (range 2.5-28.9) with rapid and sustained engraftment. Mobilization, harvesting and autografting of pegfilgrastim-mobilized PBC can be successfully achieved in pretreated patients with aggressive lymphoma.
|
Authors | A Nosari, R Cairoli, D Ciapanna, L Gargantini, L Intropido, C Baraté, B Scarpati, L Santoleri, G Nador, L Pezzetti, E Morra |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 38
Issue 6
Pg. 413-6
(Sep 2006)
ISSN: 0268-3369 [Print] England |
PMID | 16878144
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | Published online 31 July 2006. |
Chemical References |
- Antigens, CD34
- Antimetabolites, Antineoplastic
- Recombinant Proteins
- Cytarabine
- Granulocyte Colony-Stimulating Factor
- pegfilgrastim
- Polyethylene Glycols
- Filgrastim
- Cisplatin
|
Topics |
- Adult
- Aged
- Antigens, CD34
- Antimetabolites, Antineoplastic
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Cisplatin
(administration & dosage, adverse effects)
- Cytarabine
(administration & dosage, adverse effects)
- Female
- Filgrastim
- Granulocyte Colony-Stimulating Factor
(administration & dosage)
- Hematopoietic Stem Cell Mobilization
(adverse effects)
- Hodgkin Disease
(complications, therapy)
- Humans
- Lymphoma, Non-Hodgkin
(complications, therapy)
- Male
- Middle Aged
- Neutropenia
(etiology)
- Pain
- Peripheral Blood Stem Cell Transplantation
(adverse effects)
- Polyethylene Glycols
- Recombinant Proteins
- Transplantation, Autologous
|